Kallistatin, a tumor suppressor through multiple pathways (Chao et al., 2017), enhanced the expression of the tumorigenic suppressors, miR-34a and P53, in breast cancer cells (Li et al., 2016). This evidence concerns the gene TP53 and breast cancer.